Heron Therapeutics Reports Mixed Q1 2026 Results, Reaffirms Full-Year Guidance
HRTX sits 69% above its 52-week low of $0.736.
Summary
Heron Therapeutics reported a 10.8% decline in total net revenue and a net loss for Q1 2026, but its Acute Care franchise saw strong growth. The company reaffirmed its full-year guidance and settled CINVANTI patent litigation.
Key Events · Earnings and Guidance · HRTX
-
Q1 2026 Financial Performance
Total net revenue decreased 10.8% year-over-year to $34.7 million, resulting in a net loss of $8.1 million and negative Adjusted EBITDA of $0.7 million.
-
Acute Care Franchise Growth
Net revenue for the Acute Care franchise grew 32% year-over-year to $13.6 million, with ZYNRELEF up 27% to $10.2 million and APONVIE up 50% to $3.4 million.
-
Oncology Franchise Decline
Oncology Supportive Care net revenue decreased 26.3% to $21.1 million, primarily due to a 20.2% decline in CINVANTI and the planned wind-down of SUSTOL.
-
Full-Year Guidance Reaffirmed
The company reaffirmed its 2026 full-year guidance of $173–$183 million in net revenue and $10–$20 million in Adjusted EBITDA.
Analysis · HRTX · Life Sciences
Heron Therapeutics reported a decline in total net revenue and a net loss for Q1 2026, contrasting with a net income in the prior year. However, its Acute Care franchise, driven by ZYNRELEF and APONVIE, showed strong year-over-year growth. Management reaffirmed its full-year 2026 revenue and Adjusted EBITDA guidance, suggesting confidence in a recovery from Q1 seasonality and operational improvements. The settlement of CINVANTI patent litigation also removes a legal overhang.
At the time of this filing, HRTX was trading at $1.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $228.3M. The 52-week trading range was $0.74 to $2.32. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.